Trualt Bioenergy
Trualt Bioenergy
Fast Moving Consumer GoodsKey Fundamentals
MicrocapAgricultural ProductsFMCGTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Promoters have pledged 36.8% of their holding.
- Working capital days have increased from -31.2 days to 63.4 days
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoTruAlt Bioenergy Ltd is a small-cap FMCG company with a market cap of ~Rs 3,975 Cr trading at a PE of 41.4x. While the company delivered strong 3-year compounded sales growth of 31% and profit growth of 39%, the trailing twelve months show a revenue decline of 9% and profit decline of 35%, signaling a sharp recent slowdown.
- Strong 3-year compounded sales CAGR of 31%, indicating robust medium-term revenue expansion
- 3-year compounded profit CAGR of 39%, demonstrating ability to grow earnings faster than revenue over the medium term
- 3-year average ROE of 14%, reflecting decent capital efficiency over the medium term
- Price-to-book ratio of 2.64x is not excessively stretched for an FMCG company with demonstrated growth history
- Company has been reporting repeated profits, indicating a fundamentally viable business model
- Market cap of Rs 3,975 Cr places it in the small-to-mid cap space with potential runway for growth if execution recovers
- TTM revenue declined 9%, a sharp reversal from the 31% three-year CAGR, suggesting demand or execution challenges
- TTM profit declined 35%, indicating significant margin compression or operational deterioration in the most recent period
- Promoters have pledged 36.8% of their holding, raising governance and forced-selling risk
- Working capital days deteriorated sharply from -30.9 days to 64.3 days, indicating capital is getting locked up in operations
- PE of 41.4x is elevated especially given the TTM profit decline of 35%, suggesting the stock is priced for growth that is not currently materializing
- Zero dividend yield despite repeated profits indicates no direct shareholder returns
- Low interest coverage ratio suggests debt servicing burden relative to operating earnings
- Last year ROE dropped to 8% from 3-year average of 14%, showing deteriorating return on equity
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago- FY26 net profit drops 34% Jun 23
Consolidated net profit fell to ₹9,686.98 lakh in FY26 from ₹14,663.85 lakh in FY25, while revenue from operations also declined to ₹1,72,750.66 lakh.
- Large ₹2,500 Cr RPTs sought Jun 08
Trualt Bioenergy is seeking postal ballot approval for material related party transactions worth up to ₹2,500 Crores with Nirani Sugars Limited for FY 2026-27, raising governance scrutiny.
- ₹150 Cr govt aid for SAF Jun 18
Secured ₹150 crore under PM JI-VAN Yojana for a 10 crore litre Sustainable Aviation Fuel plant in Bagalkot, expanding into high-growth aviation fuel segment.
- Promoter shares unencumbered in FY26 Jun 22
Promoter Vijaykumar Murugesh Nirani declared no new encumbrances on TruAlt Bioenergy shares in FY26, complying with SEBI takeover regulations.
- Investor meet on June 12 Jun 08
TruAlt Bioenergy hosted a virtual group meeting with analysts and institutional investors on June 12, 2026 as part of the InsightX 2026-Choice Virtual Conference.
TL;DR: TruAlt Bioenergy faces a notable earnings decline with FY26 net profit down 34% and falling revenues, signaling operational pressure in its core FMCG/bioenergy business. On the positive side, the ₹150 Cr government grant for SAF diversifies its revenue base into aviation fuel. The large ₹2,500 Cr related party transactions with Nirani Sugars warrant governance monitoring. The trend is mixed — new capacity investments are forward-looking, but profitability deterioration needs to reverse for sentiment to improve.
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 388 | 415 | 907 | 304 | 115 | 713 | 596 | 627 |
| Expenses | 184 | 371 | 291 | 753 | 262 | 119 | 579 | 466 | 494 |
| Operating Profit | 14 | 17 | 125 | 154 | 42 | -5 | 134 | 129 | 133 |
| OPM % | 7% | 4.5% | 30% | 17% | 14% | -4% | 19% | 22% | 21% |
| Other Income | 15 | 17 | 15 | 14 | 23 | 15 | 18 | 31 | 15 |
| Interest | 35 | 34 | 36 | 39 | 38 | 39 | 40 | 44 | 44 |
| Depreciation | 16 | 16 | 18 | 18 | 21 | 21 | 22 | 23 | 25 |
| PBT | -22 | -16 | 86 | 111 | 6 | -49 | 90 | 94 | 78 |
| Tax % | 0% | 15% | 13% | -1% | 18% | -23% | 23% | 27% | 24% |
| Net Profit | -22 | -19 | 75 | 112 | 5 | -38 | 69 | 69 | 59 |
| EPS in Rs | -3.05 | -2.64 | 10.65 | 15.81 | 0.67 | -4.42 | 8.08 | 7.91 | 6.66 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 762 | 1,223 | 1,908 | 1,728 | 2,050 |
| Expenses | 657 | 1,035 | 1,599 | 1,438 | 1,659 |
| Operating Profit | 105 | 188 | 309 | 290 | 392 |
| OPM % | 14% | 15% | 16% | 17% | 19% |
| Other Income | 0 | 57 | 61 | 86 | 78 |
| Interest | 35 | 143 | 144 | 160 | 166 |
| Depreciation | 21 | 57 | 67 | 86 | 90 |
| PBT | 49 | 45 | 159 | 130 | 213 |
| Tax % | 28% | 29% | 8% | 25% | — |
| Net Profit | 35 | 32 | 147 | 97 | 159 |
| EPS in Rs | 5.81 | 5.21 | 20.76 | 11.19 | 18.23 |
| Div. Payout % | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 61 | 61 | 71 | 86 |
| Reserves | 179 | 204 | 698 | 1,435 |
| Borrowings | 1,150 | 1,685 | 1,557 | 1,652 |
| Other Liabilities | 465 | 469 | 704 | 606 |
| Total Liabilities | 1,856 | 2,418 | 3,030 | 3,778 |
| Fixed Assets | 1,302 | 1,427 | 1,826 | 2,185 |
| CWIP | 10 | 201 | 3 | 68 |
| Investments | 0 | 10 | 4 | 4 |
| Other Assets | 545 | 780 | 1,197 | 1,521 |
| Total Assets | 1,856 | 2,418 | 3,030 | 3,778 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 233 | 35 | 342 | -296 |
| Investing | -1,149 | -384 | -255 | -413 |
| Financing | 920 | 367 | 40 | 648 |
| Net Cash Flow | 5 | 19 | 126 | -62 |
| Free Cash Flow | -42 | -321 | 82 | -806 |
| CFO/OP | 222 | 21 | 110 | -99 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 41 | 89 | 65 | 86 |
| Inventory Days | 112 | 72 | 60 | 173 |
| Days Payable | 225 | 70 | 139 | 89 |
| Cash Conversion Cycle | -72 | 92 | -14 | 170 |
| Working Capital Days | 8 | -130 | -27 | 63 |
| ROCE % | — | 11% | 14% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Trualt Bioenergy insights
43 extracted metrics + investor summaries across FY23–FY27.
Documents
Frequently Asked Questions about Trualt Bioenergy
What does TruAlt Bioenergy Ltd do?
Where is TruAlt Bioenergy Ltd (TRUALT) listed?
Which sector does TruAlt Bioenergy Ltd belong to?
What is the market capitalisation of TruAlt Bioenergy Ltd?
What is the PE ratio of TruAlt Bioenergy Ltd?
What is the 52-week high and low of TruAlt Bioenergy Ltd?
What is the Return on Equity (ROE) of TruAlt Bioenergy Ltd?
Company Information
Incorporated in 2021, Trualt Bioenergy Limited is engaged in the production of biofuels, with a primary focus on the ethanol sector.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TRUALT.md for TruAlt Bioenergy Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.